Sveriges mest populära poddar

Season 1, Episode 21

20 min•21 maj 2020

Today we’ll review data on the high frequency of germline RUNX1 mutations in patients with acute myeloid leukemia, learn more about the development of an international prognostic score that predicts time to first treatment in CLL patients with early, asymptomatic disease, and explore the possibility of improving the activity of virus-directed immunotherapies against certain types of EBV tumors.

Fler avsnitt av Blood Podcast

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

13 aug.•33 min

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

6 aug.•17 min

FLT3-ITD microclones in AML and Results from the RESET-PV trial

30 juli•14 min

Initial CHORUS data on HHT and ASH HematOmics Program

23 juli•26 min

IV Iron during Acute Infection and Revisiting iTTP Refractoriness

16 juli•17 min

A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies

9 juli•18 min

IV Iron Risks and Low-Dose AML Gains

2 juli•25 min

Orca-T for GVHD–free survival and Understanding VEXAS anemia

25 juni•23 min

Treating AML, Before and After Relapse

18 juni•16 min

Future Directions in Relapsed and Refractory Large B-cell Lymphoma

11 juni•25 min

Blood Podcast med American Society of Hematology finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.